Annual Agreement Sample Clauses

Annual Agreement. This agreement must be signed prior to the beginning of the Extended Employment Services fiscal year by an authorized representative of the Certified Extended Employment Services Provider and the IDVR state administrator or a designee. (3-14-07)
Sample 1Sample 2Sample 3See All (9)
AutoNDA by SimpleDocs
Annual Agreement. If you have agreed to an annual services agreement, You agree that the term of duration of your Agreement shall be twelve (12) or twenty four (24) months from the installation and/or activation date (the “Term”), as specified in your Work Order or Service Order. You agree not to cancel the Services rendered under this Agreement prior to the date on which the term expires. The rates included in the Agreement are valid solely with regard to the accepted offer that may combine Services offered by Xxxxxxx. If you cancel any of the Services agreed to in the Agreement, from the time of cancellation, normal rates shall apply. If you voluntarily cancel all of the Services included in the Agreement or if they are cancelled due to your breach of the Agreement prior to the expiration of the Term, you shall be in violation of the terms established in the Agreement and you will be charged an early cancellation fee according to current laws plus the debt for the Services rendered until the end of your current billing cycle. Additionally, you understand that at the end of the original term of one (1) year, this Agreement shall renew automatically for additional terms of one (1) month each, with the current rates and discounts on the date of each renewal being applicable and any cancellation shall be effective at the end of the corresponding month. As of the automatic renewal, you may cancel the Agreement at any time without any penalty and your cancellation shall be effective at the end of the billing cycle in progress at the time of cancelling. Please refer to Section 18 for more details on Customer Termination.
Sample 1Sample 2
Annual Agreement. This agreement must be signed prior to the beginning of the EES fiscal year by an authorized representative of the provider and the IDVR State Administrator or a designee. (3-29-17)
Sample 1Sample 2
Annual Agreement. 7.1 The Partners will in each year jointly prepare an Annual Agreement setting out the framework of policies and objectives within which the North Peterborough PCT will operate in providing Health Services and Social care services. 7.2 The Annual Agreement will apply for a period from 1st April of one year to 31st March of the following year, though it will also where possible include provisional agreement about developments in later years. The Partners will agree and may from time to time amend the annual timetable for the preparation of the Annual Agreement. 7.3 The Annual Agreement will, in particular: a) Describe any agreed strategic changes which are planned in the Social care services provided by the North Peterborough PCT. b) Set out agreed objectives and targets, including agreed expectations about the outcomes to be achieved through the use of any additional funding which the Council is providing to the North Peterborough PCT. c) Indicate how the Partners anticipate that services will be affected by any growth or reduction in funding to the North Peterborough PCT. d) Set out the charges that the Council expects the North Peterborough PCT to recover on its behalf for Social care services. e) Sets out the information that the Council requires from the PCTs to demonstrate the manner in which it is fulfilling the Annual Agreement. f) Record the annual contributions of the Partners to the Pooled Fund and variations to the same. 7.4 The Annual Agreement may incorporate references to additional strategy documents which NHS bodies and the Council have produced or intend to produce, including nationally-mandated strategies, joint investment plans and other documents. 7.5 The Annual Agreement may be modified at any time during its currency by agreement in writing between the partners.
Sample 1
Annual Agreement. 6.1 The JOGMEC and COLLABORATOR agree the AGREEMENT each fiscal year (“ANNUAL AGREEMENT”) (starting from the effective date of each fiscal year and ending on 31st March) and shall perform RESEARCH PROJECT. 6.2 ANNUAL AGREEMENT shall include ANNUAL RESEARCH PLAN which provided the scope of work of RESEARCH PROJECT in the fiscal year, schedule, implementation system, and detail expense allocation of EXPERIMENT EXPENDITURE. 6.3 The JOGMEC and COLLABORATOR shall specify the contents of ANNUAL RESEARCHPLAN based on progress of RESEARCH PROJECT and conclude ANNUAL AGREEMENT. 6.4 When the JOGMEC and COLLABORATOR cannot secure the budget to perform sub-contracting, JOGMEC and COLLABORATOR can cancel to make ANNUAL AGREEMENT in terms of the fiscal year and revise RESEARCH PLAN.
Sample 1
Annual Agreement. The negotiated and duly approved Annual Agreement with respect to Duckwater Shoshone Tribe identifying those programs, services, functions, and activities, to be performed, the responsibilities of the Tribe and the responsibilities retained by the United States, the general budget category assigned, and the funds to be provided to the Tribe as the Tribe's share is hereby incorporated in its entirety in this Compact and attached hereto as Attachment #2. This Compact shall be in effect only during the term of any such Annual Agreement, or any extension of said term effected under the terms of this Compact or otherwise.
Sample 1
Annual Agreement a. The Union and District agree that the Union shall have the right to present for one (1) hour at the annual department meeting. i. If the training annual department meeting does not require a lunch break period the Union shall have the right to present for thirty (30) minutes at the beginning of the training.
Sample 1
AutoNDA by SimpleDocs

Related to Annual Agreement

  • Individual Agreement The Employer agrees not to enter into any agreement or contract with the employees covered by this Agreement individually or collectively which in any way conflicts with the terms and provisions of this Agreement.

  • Mutual Agreement This Agreement may be terminated at any time by mutual written agreement of the parties.

  • By Mutual Agreement This Agreement may be terminated by mutual agreement of the parties.

  • Individual Agreements ‌ 15.01 No employee or group of employees covered by this Agreement will enter into any contract or agreement with the Employer concerning wages or working conditions that will in any way conflict with the terms of this Agreement.

  • Total Agreement 35.01 This Agreement represents the entire agreement between the Employer and the Union and unless specifically and expressly set forth in the express written provisions for this Agreement, all rules, regulations, benefits and practices previously and presently in effect may be modified or discontinued upon advance notification to the Union.

  • AMENDMENT TO EMPLOYMENT CONTRACT DATE September, 2019 The employment contract between School District 271, Kootenai County, State of Idaho, and XXXXX XXXXXXXX for the 2019/2020 school year is hereby amended as follows: The salary to be paid this certificated employee will be changed to $24,071 placement: BA plus 22 credits on year 8.5 working 0.5 FTE for 190 days. This amendment to the contract only changes the placement and salary amount. Other items listed in the original contract remain the same.

  • Formal Agreement If the above Agreement and relating exhibits thereto are acceptable, would you please execute the acceptance and acknowledgment hereinafter provided, upon which this letter will become a binding agreement between us.

  • CONTRACTUAL AGREEMENT This Invitation for Bids shall be included and incorporated in the final contract or purchase order. The order of contract precedence will be the contract (purchase order), bid document, and response. Any and all legal actions associated with this Invitation for Bids and/or the resultant contract (purchase order) shall be governed by the laws of the State of Florida. Venue for any litigation involving this contract shall be the Ninth Circuit Court in and for Orange County, Florida.

  • Collaboration Agreement The Collaboration Agreement shall not have been terminated in accordance with its terms and shall be in full force and effect.

  • Transition Agreement In the event of termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos pursuant to Section 12.2.1, or with respect to one (1) or more countries or other jurisdictions by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i), Galapagos and AbbVie shall negotiate in good faith the terms and conditions of a written transition agreement (the “Transition Agreement”) pursuant to which AbbVie and Galapagos will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to Galapagos as reasonably necessary for Galapagos to exercise the licenses granted pursuant to Sections 12.6 or 12.7 after termination of this Agreement (in its entirety or with respect to one (1) or more countries or other jurisdictions, as applicable) as and to the extent set forth in this Article 12. For clarity, AbbVie shall not be required to Manufacture or have Manufactured the Molecules or Products by or on behalf of Galapagos as part of the Transition Agreement. 12.8.1 The Transition Agreement shall provide that in the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos in its entirety pursuant to Section 12.2.1, AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Documentation then Controlled by AbbVie or its Affiliates or Sublicensees and in its/their name applicable to the Products in the Territory that are the subject of an exclusive license grant in Section 12.6.1(iii); (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (iv) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of pre-clinical Development activities, Clinical Studies or Manufacturing activities for the Products, including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party. 12.8.2 The Transition Agreement shall provide that in the event of a termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i) (but not in the case of any termination of this Agreement in its entirety), AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Approvals owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, which Regulatory Approvals are solely applicable to the relevant country or jurisdiction and the Products that are the subject of an exclusive license grant in Section 12.7, as such Regulatory Approvals exists as of the effective date of such termination of this Agreement with respect to such relevant country or jurisdiction; provided, that AbbVie retains a license and right of reference under any Regulatory Approval transferred pursuant to this clause as necessary or reasonably useful for AbbVie to Commercialize Products in the Territory, Develop Molecules or Products in support of such Commercialization, or Manufacture Molecules or Products in support of such Development or Commercialization; (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) grant Galapagos a right of reference to all Regulatory Documentation then owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, and which Regulatory Documentation is not transferred to Galapagos pursuant to clause (i) above, and is necessary or reasonably useful for Galapagos, any of its Affiliates or sublicensees to Develop or Commercialize in the terminated country or jurisdiction the Product(s) that are the subject of the license grant in Section 12.7 as such Regulatory Documentation exists as of the effective date of such termination of this Agreement with respect to such terminated country or jurisdiction; (iv) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies specific to such terminated country(ies) being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (v) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of Clinical Studies specific to such terminated country(ies), including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!